Search company, investor...

Arno Therapeutics

arnothera.com

Founded Year

2000

Stage

PIPE | IPO

About Arno Therapeutics

Arno Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapeutics.

Headquarters Location

4 Campus Drive Second Floor

Parsippany, New Jersey, 07054,

United States

862-703-7175

Missing: Arno Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Arno Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Arno Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arno Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Arno Therapeutics Patents

Arno Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Progestogens
  • Abandoned drugs
  • Diketones
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/16/2015

9/29/2020

Progestogens, Pregnanes, Glucocorticoids, Ketones, Transcription factors

Grant

Application Date

11/16/2015

Grant Date

9/29/2020

Title

Related Topics

Progestogens, Pregnanes, Glucocorticoids, Ketones, Transcription factors

Status

Grant

Latest Arno Therapeutics News

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

May 6, 2022

and ROTTERDAM, Netherlands and SUZHOU, China, May 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment of Alexander A. Zukiwski, MD, to the Company's Scientific Advisory Board. Prior to joining CASI Pharmaceuticals Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics and had been a Director of Arno Therapeutics. Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD)and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies including Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski has more than 25 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis®, and Doxil®. He previously served as a Member of Medical Advisory Board at Gem Pharmaceuticals, LLC and served as a Director of Ambit Biosciences Corporation and currently serves as a Director of Oncolyze, Inc. Dr. Zukiwski holds a bachelor's degree in Pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center. "We're pleased to welcome Dr. Zukiwski to our Scientific Advisory Board," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "His expertise in the field of oncology and deep experience in clinical evaluation and registration will be invaluable to HBM as we grow and advance our innovative pipeline to serve patients worldwide. He will work closely with Chief Medical Officer Dr. Humphrey Gardner and rest of the management team to drive our global clinical portfolio and to optimize the pipeline strategy." "It's an honor to join the HBM Scientific Advisory Board. I'm impressed with HBM's global vision as well as innovative pipeline powered by its competitive research and development engine," commented Dr. Zukiwski. "I look forward to working with the other members of the SAB and Dr. Wang's talented team in bringing forward transformative therapeutics on a global basis." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Arno Therapeutics Frequently Asked Questions (FAQ)

  • When was Arno Therapeutics founded?

    Arno Therapeutics was founded in 2000.

  • Where is Arno Therapeutics's headquarters?

    Arno Therapeutics's headquarters is located at 4 Campus Drive, Parsippany.

  • What is Arno Therapeutics's latest funding round?

    Arno Therapeutics's latest funding round is PIPE.

  • Who are the investors of Arno Therapeutics?

    Investors of Arno Therapeutics include Pontifax, UTA Capital and Two River Group Holdings.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.